Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Brief Summary:
Background:
Sometimes the cancer advanced alveolar soft part sarcoma (ASPS) cannot be helped with surgery or other treatment. The drug atezolizumab unblocks the immune system. This allows immune cells to recognize and attack tumor cells. The drug could shrink cancer but could also have side effects. Researchers want to study if the drug will shrink a tumor in people with advanced ASPS.
Objective:
To test good and bad effects of the drug atezolizumab.
Eligibility:
People at least 6 years old with ASPS that cannot be cured with surgery
Design:
Participants will be screened with heart and pregnancy tests. Some may have scans or other tests.
At the study start, participants will have:
Each study cycle is 21 days.
In cycle 1:
In o